Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Chest MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients.Ann Thorac Surg. 2008; 85: 1919-1924
- Transplantation in highly HLA-sensitized patients: challenges and solutions.Transpl Res Risk Manag. 2014; 214: 99-107
- Clinical outcomes of lung transplantation in the presence of donor-specific antibodies.Ann Am Thorac Soc. 2019; 16: 1131-1137
- Approaches to the management of sensitized lung transplant candidates: findings from an international survey.J Heart Lung Transpl. 2020; 39: S315
- Lung transplantation and the era of the sensitized patient.Front Immunol. 2021; 12: 689420
- The impact of HLA-DR mismatch status on retransplant-free survival and bronchiolitis obliterans syndrome‒free survival among sensitized lung transplant recipients.J Heart Lung Transpl. 2020; 39: 1455-1462
- Increased cPRA is associated with increased waitlist time and mortality in LTx.Ann Thorac Surg. 2020; 110: 414-423
- Effect of calculated panel reactive antibody value on waitlist outcomes for lung transplant candidates.Ann Transpl. 2019; 24: 383-392
- Human leukocyte antigen antibody sensitization, lung transplantation, and health equity.Am J Transplant. 2022; 22: 698-704
- Hyperacute rejection following lung transplantation.Chest. 1996; 110: 559-562
- Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies.J Heart Lung Transpl Off Publ Int Soc Heart Transpl. 2007; 26: 642-645
- Early donor-specific antibodies in lung transplantation: risk factors and impact on survival.J Heart Lung Transpl. 2014; 33: 1255-1263
- Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics.Am J Transpl. 2016; 16: 1216-1228
- Detection and clinical impact of human leukocyte antigen antibodies in lung transplantation: a systematic review and meta-analysis.HLA. 2018; 91: 102-111
- Comparative analysis of how immune sensitization is defined prior to lung transplantation.Hum Immunol. 2015; 76: 711-716
- Approaching the sensitized lung patient: risk assessment for donor acceptance.J Thorac Dis. 2021; 13: 6725-6736
- Choosing the right patient for lung transplantation: assessment of histocompatibility and sensitization status.in: Bertani A. Vitulo P. Grossi P.A. Contemporary lung transplantation. Organ and tissue transplantation. Springer, Cham2020: 1-12
- Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.J Heart Lung Transpl. 2014; 33: 1074-1082
- The shared epitope phenomenon—a potential impediment to virtual crossmatch accuracy.Clin Transplant. 2020; 34: e13906
- Incidence and impact of allele-specific anti-HLA antibodies and high-resolution HLA genotyping on assessing immunologic compatibility.Hum Immunol. 2021; 82: 147-154
- Lung transplantation outcomes after crossing low-level donor specific antibodies without planned augmented immunosuppression.Clin Transpl. 2021; 35: e14447
- Survival in sensitized lung transplant recipients with perioperative desensitization: successful desensitization in lung transplant recipients.Am J Transpl. 2015; 15: 417-426
- Long-term outcomes of sensitized lung transplant recipients after peri-operative desensitization.Am J Transpl. 2021; 21: 3444-3448
- Perioperative desensitization for sensitized lung transplant candidates.J Heart Lung Transpl. 2021; 40: S371
- Postoperative outcomes of lung transplant recipients with preformed donor-specific antibodies.Interact Cardiovasc Thorac Surg. 2020; 32: 616-624
- Reduction of alloantibodies via proteosome inhibition in cardiac transplantation.J Heart Lung Transpl. 2011; 30: 1320-1326
- Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients.transplantation. 2012; 94: 345-351
- Antibody desensitization therapy in highly sensitized lung transplant candidates: antibody desensitization therapy.Am J Transpl. 2014; 14: 849-856
- Peri-operative desensitization for highly sensitized heart transplant patients.JF Heart Lung Transpl. 2018; 37: 667-670
- Clinical outcomes of perioperative desensitization in heart transplant recipients.Transpl Direct. 2021; 7: e658
- Update on the continuous distribution of organs project - OPTN.(Available at:) (Accessed May 12, 2022)
- IdeS (Imlifidase): a novel agent that cleaves human IgG and permits successful kidney transplantation across high-strength donor-specific antibody.Ann Surg. 2018; 268: 488-496
- Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.Am J Transplant. 2021; 21: 3907-3918
- Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial.Am J Transplant. 2019; 19: 2876-2888
- Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies.Am J Transplant. 2018; 19: 1671-1683
- Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients 2011M.Am J Transpl. 2013; 13: 241
- Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.Am J Transplant. 2011; 11: 2405-2413
- Acute antibody-mediated rejection 1 week after lung transplantation successfully treated with eculizumab, intravenous immunoglobulins, and rituximab.Transplantation. 2018->; 102: e301-e303
- Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab.J Heart Lung Transplant. 2012; 31: 1325-1326
- C1-Esterase-Inhibitor counteracts severe primary graft dysfunction in lung transplantation.J Heart Lung Transplant. 2013; 32: S222
- Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria.N Engl J Med. 2021 Mar 18; 384: 1028-1037
- Preclinical analysis of candidate anti-human CD79 therapeutic antibodies using a humanized CD79 mouse model.J Immunol. 2022; 208: 1566-1584
- Emerging B-Cell therapies in systemic lupus erythematosus.Ther Clin Risk Manag. 2021; 17: 39-54
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.Arthritis Rheum. 2011; 63: 3918-3930
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
